Published in J Infect Dis on December 01, 1979
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest (1992) 1.62
Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 1.52
Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44
Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae (2011) 1.19
The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation. Clin Exp Immunol (1985) 1.07
The influence of cytomegalovirus carrier status on lymphocyte subsets and natural immunity. Clin Exp Immunol (1987) 1.03
Modulation of natural killer cell activity in mice after interferon induction: depression of activity and depression of in vitro enhancement by interferon. Infect Immun (1982) 0.95
Lymphocyte subsets and natural killer cell responses during cytomegalovirus mononucleosis. Infect Immun (1983) 0.92
Cytomegalovirus infection in infancy: virological and immunological studies. Clin Exp Immunol (1982) 0.88
Regulatory function of cytomegalovirus-specific CD4+CD27-CD28- T cells. Virology (2009) 0.88
Suppression of monocyte functions by human cytomegalovirus. Immunology (1989) 0.87
Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun (1981) 0.86
Effects of vaccines on the canine immune system. Can J Vet Res (1989) 0.82
Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function. J Infect Dis (2014) 0.81
Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection. Clin Exp Immunol (1985) 0.80
Cytomegalovirus-specific cell-mediated immunity in lower-socioeconomic-class adolescent women with local cytomegalovirus infections. J Clin Microbiol (1983) 0.79
Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. II. Secondary CMV infections associated with impaired in vitro proliferative responses to mitogens, allogeneic lymphocytes and CMV infected cells. Clin Exp Immunol (1985) 0.77
Blastogenic response of human lymphocytes to early antigen(s) of human cytomegalovirus. Infect Immun (1983) 0.77
The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence. Clin Exp Immunol (1988) 0.76
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med (1993) 5.67
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet (1987) 4.33
Macrophages and age-dependent resistance to Herpes simplex virus in mice. J Immunol (1970) 4.15
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
A nondefective (competent) adenovirus-SV40 hybrid isolated from the AD.2-SV40 hybrid population. Proc Natl Acad Sci U S A (1969) 3.81
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother (1979) 3.61
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice. J Immunol (1970) 3.49
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med (1991) 3.05
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. V. Isolation of additional hybrids which differ in their simian virus 40-specific biological properties. J Virol (1973) 2.87
An unusual infection due to staphylococcus aureus. N Engl J Med (1971) 2.68
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J Infect Dis (1977) 2.65
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol (1994) 2.50
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Opportunistic lung infection due to "Pittsburgh Pneumonia Agent". N Engl J Med (1979) 2.49
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
New bacterial agent of pneumonia isolated from renal-transplant recipients. Lancet (1979) 2.45
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men. Ann Intern Med (1989) 2.44
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (1980) 2.41
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med (1982) 2.37
Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol (1986) 2.37
Immunopathology of lymphocytic choriomeningitis viurs infection of newborn mice. Antithymocyte serum effects on glomerulonephritis and wasting disease. J Exp Med (1968) 2.31
Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis (1977) 2.30
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Variables influencing condom use in a cohort of gay and bisexual men. Am J Public Health (1988) 2.26
Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology (1998) 2.26
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med (1988) 2.18
Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med (1988) 2.17
Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr (2000) 2.13
Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol (1999) 2.11
Rapid detection of respiratory syncytial virus in nasopharyngeal secretions by enzyme-linked immunosorbent assay. J Clin Microbiol (1985) 2.10
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med (1983) 2.03
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VII. Characterization of the simian virus 40 RNA species induced by five nondefective hybrid viruses. J Virol (1973) 2.02
Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA (1990) 2.00
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
Virus-specific nucleic acids in SV40-exposed hamster embryo cell lines: correlation with S and T antigens. Proc Natl Acad Sci U S A (1969) 1.97
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet (1986) 1.96
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Use of subgenomic poliovirus DNA hybridization probes to detect the major subgroups of enteroviruses. J Clin Microbiol (1984) 1.90
Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med (1983) 1.90
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Effects of anti-lymphoid sera on viral infections. Lancet (1968) 1.87
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Detection of parasite DNA in Chagas' heart disease. Lancet (1995) 1.86
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation (1997) 1.84
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med (1985) 1.83
Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis (1981) 1.81
Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis (1988) 1.81